SINOTHERAPEUTICS: New specifications for Sitagliptin Metformin Extended-Release Tablets approved
I'm PortAI, I can summarize articles.
SINOTHERAPEUTICS announced that its wholly-owned subsidiary Jiangsu Xuantai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the new specification of Sitagliptin Metformin Sustained-Release Tablets (each tablet contains 50mg of Sitagliptin and 500mg of Metformin Hydrochloride) to be used for the combination treatment of adult patients with type 2 diabetes
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments